Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6553744 | 0.82 | CA12 (0.49) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL6616356 | 0.81 | — | — | |
| Water SCHEMBL8623502 | 0.79 | KDM4C (0.38) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL8623804 | 0.79 | KDM6B (0.40) | CA12CA1CA2CA9CA14 | |
| SCHEMBL6622318 | 0.79 | L3MBTL1 (0.32) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7950744 | 0.78 | TAAR1 (0.41) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL8626608 | 0.78 | KDM6B (0.41) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL6618073 | 0.78 | EGFR (0.43) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL7952129 | 0.78 | ALDH1A1 (0.53) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL6617228 | 0.77 | CA12 (0.36) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0877748-B1 | PYRIDO-1,2,4-THIADIAZINE AND PYRIDO-1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | UNIV LIEGE (BE) | 2004-11-03 | — | — | EP | claimed |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | claimed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | claimed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | claimed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | claimed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | claimed |
| US-5792764-A | ENDOCRINE DISORDERS ESPECIALLY AS A K(ATP)-CHANNEL MODULATOR | NOVO NORDISK A/S (DK) | 1998-08-11 | — | — | US | claimed |
| US-20200163902-A1 | THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-05-28 | — | — | US | disclosed |
| US-10583094-B2 | Therapeutic methods that target the NCCA-ATP channel | UNIVERSITY OF MARYLAND (US) | 2020-03-10 | — | — | US | disclosed |
| US-20170112860-A1 | NOVEL NON-SELECTIVE CATION CHANNEL IN NEURONAL CELLS AND METHODS FOR TREATING BRAIN SWELLING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | disclosed |
| US-20150272964-A1 | NOVEL NON-SELECTIVE CATION CHANNEL IN NEURONAL CELLS AND METHODS FOR TREATING BRAIN SWELLING | U.S. OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS | 2015-10-01 | — | — | US | disclosed |
| US-8980952-B2 | Methods for treating brain swelling with a compound that blocks a non-selective cation channel | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2359832-A2 | Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof | University of Maryland, Baltimore (US) | 2011-08-24 | — | — | EP | disclosed |
| US-6242443-B1 | 1,2,4-benzothiadiazine derivatives, their preparation and use | NOVO NORDISK AIS (DK) | 2001-06-05 | — | — | US | disclosed |
| US-6232310-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2001-05-15 | — | — | US | disclosed |
| US-6225310-B1 | Fused 1,2,4-thiadiazine derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 2001-05-01 | — | — | US | disclosed |
| US-6147098-A | USEFUL IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGIC SYSTEM | NOVO NORDISK A/S (DK) | 2000-11-14 | — | — | US | disclosed |
| US-5955548-A | POTASSIUM CHANNEL MODULATORS | NOVO NORDISK A/S (DK) | 1999-09-21 | — | — | US | disclosed |
| US-5889002-A | CENTRAL NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS; ENDOCRINAL DISEASES | NOVO NORDISK A/S (DK) | 1999-03-30 | — | — | US | disclosed |
| US-5792764-A | ENDOCRINE DISORDERS ESPECIALLY AS A K(ATP)-CHANNEL MODULATOR | NOVO NORDISK A/S (DK) | 1998-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125323-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ1, KCNJ2 | CA12 3774/4885CA1 3553/4885CA2 1165/4885 |
| US-20030109519-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ2, KCNJ1 | CA12 4414/4885CA1 4203/4885CA2 1241/4885 |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | KCNN3, KCNN1, KCNN2 | CA12 1900/4885CA1 1153/4885CA2 413/4885 |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | CD69, IAPP, CD4 | CA12 3430/4885CA1 1320/4885CA2 2011/4885 |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | KCNN3, KCNN2, KCNN1 | CA12 4601/4885CA1 2987/4885CA2 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.